Why should AMGN buy ONXX at a whopping 9.6x 2014 rev estimates(Yahoo) vs.... LESS than 1x for ....S V N T ?
And SVNT's orphan drug is already approved in both the US & EU and has enormous pricing-power going forward. For ex., SVNT's orphan rare disease therapy Krystexxa is currently priced at only $5,390/dose vs over $34,000/dose for similar rare disease therapies like Acthar. In addition, Krystexxa has label expansion opportunities in 1)Organ Transplant , 2)Dialysis, 3)Induction Maintenance and 4)Tumor Lysis Syndrome. SVNT is worth a minimum of $5-$6/sh by YE after they align Krystexxa's price to rare disease levels. Good luck to all.